GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
80.95
-0.46 (-0.57%)
At close: 4:00PM EST

81.10 +0.15 (0.19%)
After hours: 7:37PM EST

Stock chart is not supported by your current browser
Previous Close81.41
Open81.23
Bid80.92 x 100
Ask81.10 x 100
Day's Range80.91 - 82.18
52 Week Range63.76 - 86.27
Volume7,198,762
Avg. Volume8,226,233
Market Cap105.743B
Beta0.87
PE Ratio (TTM)9.21
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.08 (2.57%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals10 hours ago

    Gilead, Parker Institute grab stakes in Penn immunotherapy spinout's $100 million round

    Gilead Sciences Inc. took another step toward building out its immunotherapy program as part of a $100 million Series A financing for a Philadelphia company. The San Francisco-based Parker Institute for Cancer Immunotherapy, which has championed new research and alliances around ways to use the body's immune system to beat back cancer, also participated in the private stock sale for University of Pennsylvania spinout Tmunity Therapeutics Inc. Co-founded in 2015 by Penn T-cell therapy pioneer Dr. Carl June, Tmunity is developing a diversified portfolio of novel treatments that involve re-engineering a person's own infection-fighting T cells to boost the patient's ability to fight disease.

  • Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion
    Zacks12 hours ago

    Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

    Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.

  • Forbesyesterday

    Celgene Buys Juno Therapeutics: A Risky $9B Bet

    Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. Critics worry this wager may fail to help the biotech giant fill the gaps in its revenue stream.

  • Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?
    Motley Foolyesterday

    Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?

    The price tag is actually higher than you think. But the payoff might be, too.

  • 3 Stocks the World's Best Investors Are Buying Right Now
    Motley Foolyesterday

    3 Stocks the World's Best Investors Are Buying Right Now

    Some of the best investors in the world are buying shares of these companies, and for good reason.

  • Healthcare ETFs to Watch As Q4 Earnings Unfold
    Zacksyesterday

    Healthcare ETFs to Watch As Q4 Earnings Unfold

    With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.

  • Analysts’ Future Estimates for Merck & Co.
    Market Realistyesterday

    Analysts’ Future Estimates for Merck & Co.

    Who’s Watching Merck & Co. in January 2018?

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
    Motley Fool2 days ago

    Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.

    Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?

  • Gilead Collaborates with Pfizer for Yescarta Combo Study
    Zacks4 days ago

    Gilead Collaborates with Pfizer for Yescarta Combo Study

    Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.

  • GuruFocus.com4 days ago

    CVS and Gilead Sciences Hit the Casualty List

    Starving in the midst of plenty, some stocks got roughed up in the fourth quarter even as the market rose

  • Which Biotech Stocks Could Surprise To The Upside On Earnings?
    Investor's Business Daily4 days ago

    Which Biotech Stocks Could Surprise To The Upside On Earnings?

    Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.

  • Barrons.com4 days ago

    Gilead Earnings: Don't Get Too Excited

    Shares of Gilead Sciences (GILD) didn't have a great 2017, and analysts are split on whether or not the stock will find its footing  this year, as biotech stocks face a challenging 2018. Guggenheim's Tony Bulter and his team reiterated a Neutral rating on Gilead Friday, as part of their biotech earnings preview. Butler writes that  its eroding Hepatitis C (HCV) drug sales continues to impact earnings, but that those declines could start to bottom out in the second half of this year.

  • Merck & Co.’s Human Vaccines Business in 3Q17
    Market Realist5 days ago

    Merck & Co.’s Human Vaccines Business in 3Q17

    Who’s Watching Merck & Co. in January 2018?

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug
    Market Realist5 days ago

    Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug

    Who’s Watching Merck & Co. in January 2018?

  • InvestorPlace5 days ago

    Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive

    Celgene Corp. (NASDAQ:CELG), best known for the psoriasis medicine Otezla and a number of cancer drugs, like Revlimid and Vidaza, sent the stock of Juno Therapeutics Inc. (NASDAQ:JUNO) up 55% on Jan. 17 when it was reported to be buying it. An acquisition probably won’t change a lot for CELG stock. The rumored price for Juno would be $10-12 billion, not a big deal when Celgene is worth $80 billion, but Juno was only worth $5.6 billion on Jan. 12.

  • Motley Fool5 days ago

    Healthcare: Is Celgene Going to Buy Juno Therapeutics?

    A big biotech merger could be in the works.

  • Merck & Co., Inc. Stock Could Still Soar Another 10% From Here
    InvestorPlace5 days ago

    Merck & Co., Inc. Stock Could Still Soar Another 10% From Here

    While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. All told, Merck stock is up more than 10% this year.

  • 3 Top-Ranked Drug Stocks That Are Broker Favorites
    InvestorPlace5 days ago

    3 Top-Ranked Drug Stocks That Are Broker Favorites

    Pharma and biotech stocks made an impressive comeback in 2017 with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18.7% and 11.8%, respectively. Immuno-oncology remains a key focus area with Gilead acquiring Kite last year for $11.9 billion and Celgene Corporation (NASDAQ:CELG) currently rumored to be interested in acquiring Juno Therapeutics Inc (NASDAQ:JUNO).

  • InvestorPlace6 days ago

    No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop

    Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. Juno Therapeutics is a pioneer in the booming cell therapy industry, where biotech companies are developing modified human immune cells to combat cancer cells.

  • What's Juno Therapeutics Worth to Celgene?
    Motley Fool6 days ago

    What's Juno Therapeutics Worth to Celgene?

    Celgene may be considering a multibillion-dollar bid to acquire Juno.

  • Reuters6 days ago

    Florida man gets prison for trading on tip about Gilead deal

    Jay Fung, of Delray Beach, was sentenced by U.S. District Judge Anne Thompson in Trenton, New Jersey, after pleading guilty in March 2016 to conspiracy to commit securities fraud, prosecutors said. The former Morgan Stanley broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the U.S. Securities and Exchange Commission.

  • Florida man gets prison for trading on tip about Gilead deal
    Reuters6 days ago

    Florida man gets prison for trading on tip about Gilead deal

    A Florida man was sentenced on Wednesday to one year in prison for engaging in insider trading based on a tip he received from an ex-Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, prosecutors said. Jay Fung, of Delray Beach, was sentenced by U.S. District Judge Anne Thompson in Trenton, New Jersey, after pleading guilty in March 2016 to conspiracy to commit securities fraud, prosecutors said. The former Morgan Stanley broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the U.S. Securities and Exchange Commission.

  • Best bets for growth at record highs
    CNBC Videos5 hours ago

    Best bets for growth at record highs

    Biotech and tech surge. What to buy in a raging rally, with CNBC's Melissa Lee and the Fast Money traders.